BCTG Avocats has advised, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, as part of its €27 million Series B financing.
The round was co-led by Andera Partners and Bpifrance, as part of the InnoBio investment strategy.
The BCTG team was led by Severin Kullmann with Paul Truck and Paul Leconte.
More details here
See also...
BCTG X Labeyrie Fine Foods
Published on 16 July 2026 at 13h05
BCTG Avocats advises Cyllene Therapeutics on its €33 million funding round
Published on 09 July 2026 at 9h45
Décideurs 2026 : BCTG Avocats ranked in Africa Desk
Published on 30 April 2026 at 14h53